Want to see SE:BONEX full AI Analyst Report?
Earnings Data
Report Date
Jul 16, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.13Last Year’s EPS
0.79Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational picture: strong underlying demand and significant constant-currency revenue growth (notably in the U.S. for CERAMENT G), high gross margins, solid adjusted profitability and robust cash generation. Strategic progress was highlighted by clinical publications, first sales in India, early spine activity, and a favorable CMS proposed ruling that could materially improve reimbursement. Offsetting risks include material currency translation headwinds that reduced reported growth, a tariff-driven margin headwind in the U.S., higher short‑term commercial and incentive costs that will press margins while investments ramp, early-stage/soft BVF spine revenues and timing uncertainty around the CERAMENT V De Novo approval. On balance, the positives (strong growth momentum, cash generation, margin levels, reimbursement progress) materially outweigh the challenges.Company Guidance
Strong top-line growth (constant currency)
Net sales SEK 324 million in Q1 2026; growth of 31% at constant exchange rates versus Q1 2025 (reported growth 14% due to currency effects). Last 12 months sales growth shown as 22% reported, corresponding to 35% at constant exchange rates.
Robust U.S. momentum for CERAMENT G
U.S. sales SEK 267 million (growth 35% at constant exchange rates). CERAMENT G sales reached SEK 222 million in the quarter (vs SEK 178 million in Q1 2025, ≈+24.7%). Record sequential CERAMENT G growth of USD 2.6 million quarter-over-quarter (strongest ever).
Broad antibiotic-eluting product growth
Antibiotic-eluting CERAMENT grew 48% last 12 months at constant exchange rates; CERAMENT BVF (U.S.) last 12-month sales flat year-over-year at constant exchange rates while new spine launch is in early stages.
Profitability and strong margins
Adjusted operating result ~SEK 85 million (adjusted operating margin ~26%). Gross margin remained very high at 94.5%. FX-adjusted operating margin 25.5% in Q1 versus 22.6% in prior-year quarter (+2.9 percentage points).
Excellent cash generation and balance sheet
Operating cash flow SEK 75 million for the quarter; cash position SEK 455 million at quarter end. Reported average cash conversion since Q3 2024 is 81% and Q1 reported ahead of that average.
Regulatory and reimbursement progress
CERAMENT V De Novo process progressing with FDA questions being addressed (responses due no later than end-August). U.S. CMS proposed FY2027 IPPS ruling favorable for CERAMENT: improved payments, more specific procedure codes and proposed NTAP for CERAMENT V (conditional on timely FDA approval) — a positive validation of product value and potential to lower financial barriers to use.
Geographic expansion and clinical evidence support
EUROW sales SEK 57 million (+16% at constant exchange rates vs strong Q1 2025). First CERAMENT sales in India achieved in Q1. Two U.S. clinical publications (trauma pilot and open-fracture case series) published during the quarter supporting real-world use and adoption.
SE:BONEX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:BONEX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 22, 2026 | kr257.00 | kr254.00 | -1.17% |
Feb 24, 2026 | kr180.80 | kr187.40 | +3.65% |
Oct 23, 2025 | kr255.60 | kr238.40 | -6.73% |
Jul 15, 2025 | kr296.60 | kr311.60 | +5.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BONESUPPORT HOLDING AB (SE:BONEX) report earnings?
BONESUPPORT HOLDING AB (SE:BONEX) is schdueled to report earning on Jul 16, 2026, TBA (Confirmed).
What is BONESUPPORT HOLDING AB (SE:BONEX) earnings time?
BONESUPPORT HOLDING AB (SE:BONEX) earnings time is at Jul 16, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BONESUPPORT HOLDING AB stock?
The P/E ratio of BONESUPPORT HOLDING AB is N/A.
What is SE:BONEX EPS forecast?
SE:BONEX EPS forecast for the fiscal quarter 2026 (Q2) is 1.13.